Sirna Therapeutics

The GGV Capital Portfolio

Sirna Therapeutics

Biotech company using RNA interference-based therapies to change how diseases are treated

"GGV Capital’s public market experience helped Sirna successfully access the public markets to further our leading position in developing RNA i-based therapeutics." - Howard Robin, President & CEO

March 2006: IPO (NASDAQ: SRNA)
October 2006: Acquired by Merck & Co. (NYSE: MRK)

Next Company »